Virtual Reality Relaxation for Patients With a Psychiatric Disorder: Crossover Randomized Controlled Trial.
anxiety
depression
negative affect
positive affect
randomized controlled trial
relaxation
stress
virtual reality
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
15 01 2021
15 01 2021
Historique:
received:
10
12
2019
accepted:
25
08
2020
revised:
29
05
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Virtual reality (VR) relaxation is a promising mental health intervention that may be an effective tool for stress reduction but has hardly been tested in clinical trials with psychiatric patients. We developed an easy-to-use VR self-management relaxation tool (VRelax) with immersive 360° nature videos and interactive animated elements. To investigate the immediate effects of VR relaxation on negative and positive affective states and short-term effects on perceived stress and symptoms in patients with a psychiatric disorder, compared to standard relaxation exercises. A randomized crossover trial was conducted in 50 patients receiving ambulatory treatment for anxiety, psychotic, depressive, or bipolar disorder. Participants were randomly assigned to start with VRelax or standard relaxation and used both interventions for 10 days at home. They completed 8 visual analog scales of momentary negative and positive affective states before and after each session. Global perceived stress and psychiatric symptoms were measured before and after both intervention periods. Treatment effects were analyzed with multilevel mixed model regression analyses and 2-way analysis of variance. Both VRelax and standard relaxation exercises led to a statistically significant immediate improvement of all negative and positive affective states. Compared to standard relaxation, VRelax resulted in a significantly greater reduction of total negative affective state (change 16.2% versus 21.2%; t If the results of this trial are replicated and extended, VRelax may provide a much-needed, effective, easy-to-use self-management relaxation intervention to enhance psychiatric treatments. Netherlands Trial Register NTR7294; https://www.trialregister.nl/trial/7096.
Sections du résumé
BACKGROUND
Virtual reality (VR) relaxation is a promising mental health intervention that may be an effective tool for stress reduction but has hardly been tested in clinical trials with psychiatric patients. We developed an easy-to-use VR self-management relaxation tool (VRelax) with immersive 360° nature videos and interactive animated elements.
OBJECTIVE
To investigate the immediate effects of VR relaxation on negative and positive affective states and short-term effects on perceived stress and symptoms in patients with a psychiatric disorder, compared to standard relaxation exercises.
METHODS
A randomized crossover trial was conducted in 50 patients receiving ambulatory treatment for anxiety, psychotic, depressive, or bipolar disorder. Participants were randomly assigned to start with VRelax or standard relaxation and used both interventions for 10 days at home. They completed 8 visual analog scales of momentary negative and positive affective states before and after each session. Global perceived stress and psychiatric symptoms were measured before and after both intervention periods. Treatment effects were analyzed with multilevel mixed model regression analyses and 2-way analysis of variance.
RESULTS
Both VRelax and standard relaxation exercises led to a statistically significant immediate improvement of all negative and positive affective states. Compared to standard relaxation, VRelax resulted in a significantly greater reduction of total negative affective state (change 16.2% versus 21.2%; t
CONCLUSIONS
If the results of this trial are replicated and extended, VRelax may provide a much-needed, effective, easy-to-use self-management relaxation intervention to enhance psychiatric treatments.
TRIAL REGISTRATION
Netherlands Trial Register NTR7294; https://www.trialregister.nl/trial/7096.
Identifiants
pubmed: 33448933
pii: v23i1e17233
doi: 10.2196/17233
pmc: PMC7846446
doi:
Banques de données
NTR
['NTR7294']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17233Informations de copyright
©Wim Veling, Bart Lestestuiver, Marieke Jongma, H J Rogier Hoenders, Catheleine van Driel. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 15.01.2021.
Références
Cyberpsychol Behav Soc Netw. 2010 Oct;13(5):503-12
pubmed: 20950174
Physiol Behav. 2013 Jun 13;118:240-50
pubmed: 23688947
Annu Rev Public Health. 2014;35:207-28
pubmed: 24387090
J Med Internet Res. 2014 Jul 08;16(7):e167
pubmed: 25004803
JMIR Ment Health. 2017 Mar 29;4(1):e9
pubmed: 28356241
Clin Psychol Rev. 2007 Apr;27(3):307-17
pubmed: 17169470
Psychol Med. 2017 Oct;47(14):2393-2400
pubmed: 28325167
J Med Internet Res. 2018 Nov 30;20(11):e11152
pubmed: 30504121
PLoS One. 2014 Apr 24;9(4):e96110
pubmed: 24763812
Front Psychol. 2018 Oct 30;9:2057
pubmed: 30425671
BMJ. 2005 Nov 26;331(7527):1231
pubmed: 16308382
Psychol Sci. 2008 Dec;19(12):1207-12
pubmed: 19121124
Annu Rev Clin Psychol. 2005;1:607-28
pubmed: 17716101
Psychol Med. 2018 Feb;48(3):362-391
pubmed: 28735593
Front Psychiatry. 2019 Jul 19;10:505
pubmed: 31379623
Clin Rehabil. 2013 Apr;27(4):291-8
pubmed: 22843353
Autism Res Treat. 2012;2012:839792
pubmed: 22928101
Int J Environ Res Public Health. 2015 Dec 14;12(12):15860-74
pubmed: 26694426
Aerosp Med Hum Perform. 2017 Jun 1;88(6):520-526
pubmed: 28539139
Front Psychol. 2019 Mar 12;10:479
pubmed: 30914996
Cyberpsychol Behav Soc Netw. 2012 Jan;15(1):24-30
pubmed: 22032797
Cochrane Database Syst Rev. 2008 Oct 08;(4):CD007142
pubmed: 18843744
Asian Nurs Res (Korean Soc Nurs Sci). 2012 Dec;6(4):121-7
pubmed: 25031113
Psychol Rev. 2005 Apr;112(2):417-45
pubmed: 15783292
BMC Psychiatry. 2008 Jun 02;8:41
pubmed: 18518981
Psychiatry Clin Neurosci. 2019 Nov;73(11):669-675
pubmed: 31215710
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
World Psychiatry. 2019 Jun;18(2):192-207
pubmed: 31059629
Arch Psychiatr Nurs. 2015 Feb;29(1):6-13
pubmed: 25634868
Nat Rev Drug Discov. 2012 Feb 01;11(2):141-68
pubmed: 22293568
Int J Environ Res Public Health. 2016 Aug 03;13(8):
pubmed: 27527193
Aerosp Med Hum Perform. 2016 Dec 1;87(12):1021-1030
pubmed: 28323588
JAMA Psychiatry. 2016 Jun 1;73(6):565-74
pubmed: 27119968
Cogn Neuropsychiatry. 2017 Jan;22(1):83-94
pubmed: 27996635
Psychol Assess. 2019 Feb;31(2):139-158
pubmed: 30234319
BJPsych Open. 2016 Nov 23;2(6):366-372
pubmed: 29018562
Psychol Med. 2008 Jan;38(1):101-11
pubmed: 17903336
Nat Rev Neurosci. 2005 Apr;6(4):332-9
pubmed: 15803164
Front Psychol. 2017 Feb 27;8:268
pubmed: 28289398
Clin Psychol Rev. 2010 Dec;30(8):1011-8
pubmed: 20691523
J Clin Epidemiol. 2012 Mar;65(3):301-8
pubmed: 22169081
PLoS One. 2013 May 01;8(5):e62817
pubmed: 23650531
Psychol Med. 2009 Sep;39(9):1533-47
pubmed: 19215626
Stat Methods Med Res. 2016 Jun;25(3):1057-73
pubmed: 26092476